To Prevent Teenage Pregnancies in Sub Saharan Africa, It Takes a Whole Village to Raise a Child
Honorine Meda became pregnant herself at the age of nineteen. Now she helps raise awareness of teenage pregnancy among girls in Dissin.By Guy DinmoreDISSIN, Burkina Faso, Jul 28 2021 (IPS) Honorine Meda is 23. Cycling through her hometown of Dissin, in Burkina Faso’s verdant southwest, she smiles, waves and stops to chat with one of the girls she counsels. Thanks to a program by the German development agency (GIZ) and their Pro Enfant initiative, Honorine trained to counsel teenage girls in Dissin on how to avoid pregnancies. She became pregnant herself, with her now three-year-old son, when she was 19. It was tough...
Source: IPS Inter Press Service - Health - July 28, 2021 Category: International Medicine & Public Health Authors: Guy Dinmore Tags: Africa Aid Crime & Justice Economy & Trade Education Featured Gender Violence Headlines Health Human Rights TerraViva United Nations Women's Health GIZ 2021 Source Type: news

Screening for Duchenne Muscular Dystrophy Now Available for All Babies Born at the Brigham
The Brigham is the first birth hospital in the nation to develop a program that offers parents an option to have their newborn screened for Duchenne; through early diagnosis, screening may help families take advantage of therapeutic interventions (Source: BWH News)
Source: BWH News - July 22, 2021 Category: Hospital Management Source Type: news

A small molecule induces readthrough of cystic fibrosis CFTR nonsense mutations
(University of Alabama at Birmingham) An experimental drug reported in Nature Communications suggests that a " path is clearly achievable " to treat currently untreatable cases of cystic fibrosis disease caused by nonsense mutations. This includes about 11 percent of cystic fibrosis patients, as well as patients with other genetic diseases, including Duchenne muscular dystrophy,β-thalassemia and numerous types of cancers, that are also caused by nonsense mutations. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 19, 2021 Category: International Medicine & Public Health Source Type: news

Pupillary light reflex markers of suicide risk in a trans-diagnostic sample - Miller BJ, Sareddy S, Rosenquist PB, McCall WV.
[The publisher has not provided an abstract for this article.] Language: en... (Source: SafetyLit)
Source: SafetyLit - July 17, 2021 Category: International Medicine & Public Health Tags: Risk Factor Prevalence, Injury Occurrence Source Type: news

AP blasted for article sympathetic to fleeing Texas Dems: 'If scrambling for attention is stressful, tough'
The Associated Press came under fire Friday for its seemingly sympathetic article on Texas state Democrats who fled to Washington, D.C.... (Source: Reuters: Health)
Source: Reuters: Health - July 16, 2021 Category: Consumer Health News Source Type: news

Stellate Ganglion Phototherapy Promising for Electrical Storm Stellate Ganglion Phototherapy Promising for Electrical Storm
SG phototherapy reduced sympathetic activity and might be a useful temporary adjunctive therapy to control electrical storm, a pilot study finds.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 8, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

What We Learned About Relationships During the Pandemic
The pseudo-scientific formula that explains most human bonding is basically time + affection + togetherness = relationship. So what happens to humans and their interconnectedness when two of the key elements—time and togetherness—are removed or increased? Can digital communication replace human to human contact? How do couples cope with stressful events they have never before encountered? This is the focus of a series of studies published in the Journal of Social and Personal Relationships, which has dedicated several special issues to relationships in the time of COVID-19. “When COVID hit it became clear...
Source: TIME: Science - July 6, 2021 Category: Science Authors: Belinda Luscombe Tags: Uncategorized COVID-19 Source Type: news

What We Learned About Relationships During the Pandemic
The pseudo-scientific formula that explains most human bonding is basically time + affection + togetherness = relationship. So what happens to humans and their interconnectedness when two of the key elements—time and togetherness—are removed or increased? Can digital communication replace human to human contact? How do couples cope with stressful events they have never before encountered? This is the focus of a series of studies published in the Journal of Social and Personal Relationships, which has dedicated several special issues to relationships in the time of COVID-19. “When COVID hit it became clear...
Source: TIME: Health - July 6, 2021 Category: Consumer Health News Authors: Belinda Luscombe Tags: Uncategorized COVID-19 Source Type: news

What Problems are Ciliopathies Associated With?
Discussion Nephronophthisis (NPHP) one cause of end-stage renal disease (ESRD) usually occurring before age 30 years. NPHP is a non-motile ciliopathy affecting cellular sensing in the renal tubular epithelium. See To Learn More below. The incidence varies according to location with 1:1 million in the US but 1:50,000 in Finland. There are 3 subtypes: Infantile Occurs usually within 1 year of life Enlarged kidneys and severe hypertension In utero can have oligohydramnios problems such as pulmonary hypoplasia, facial dysmorphisms, limb contractures Extra-renal problems include congenital heart disease, liver fibrosis, recur...
Source: PediatricEducation.org - July 5, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Roche ’s ENSPRYNG approved by European Commission as first and only at-home subcutaneous treatment for neuromyelitis optica spectrum disorder (NMOSD)
Basel, 28 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) has approved ENSPRYNG ® (satralizumab) for the treatment of adults and adolescents from 12 years of age living with anti-aquaporin-4 antibody (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD), as a monotherapy or in combination with immunosuppressive therapy (IST). ENSPRYNG is the first and only NMO SD treatment that is administered subcutaneously every four weeks, allowing home-dosing after appropriate training.“An NMOSD relapse can be devastating, causing permanent neurological damage ...
Source: Roche Media News - June 28, 2021 Category: Pharmaceuticals Source Type: news

Roche ’s ENSPRYNG approved by European Commission as first and only at-home subcutaneous treatment for neuromyelitis optica spectrum disorder (NMOSD)
Basel, 28 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) has approved ENSPRYNG ® (satralizumab) for the treatment of adults and adolescents from 12 years of age living with anti-aquaporin-4 antibody (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD), as a monotherapy or in combination with immunosuppressive therapy (IST). ENSPRYNG is the first and only NMO SD treatment that is administered subcutaneously every four weeks, allowing home-dosing after appropriate training.“An NMOSD relapse can be devastating, causing permanent neurological damage ...
Source: Roche Investor Update - June 28, 2021 Category: Pharmaceuticals Source Type: news

Welcome to the normal of an undocumented migrant – Joseph’s story
This Refugee Week, Doctors of the World are introducing the members of its National Health Advisors, an advisory group of people with lived experience of migration and healthcare exclusion, to ensure migrants have a greater influence over healthcare policy and practice.      Joseph is one of the DOTW National Health Advisors, and he wants to share his story with you. – In March 2020, I had some severe symptoms of COVID-19. I was struggling to breathe so I phoned 111 and was told to go to A&E. When I arrived, I saw a big sign outside and inside the A&E saying that you ...
Source: Doctors of the World News - June 17, 2021 Category: International Medicine & Public Health Authors: Britney Sacopon Tags: Uncategorised Source Type: news

What Are the Stages of Muscular Dystrophy?
Title: What Are the Stages of Muscular Dystrophy?Category: Diseases and ConditionsCreated: 6/17/2021 12:00:00 AMLast Editorial Review: 6/17/2021 12:00:00 AM (Source: MedicineNet Kids Health General)
Source: MedicineNet Kids Health General - June 17, 2021 Category: Pediatrics Source Type: news

What makes us sneeze?
(Washington University School of Medicine) What exactly triggers a sneeze? A team led by researchers at Washington University School of Medicine in St. Louis has identified, in mice, specific cells and proteins that control the sneeze reflex. Better understanding of what causes us to sneeze -- specifically how neurons behave in response to allergens and viruses -- may point to treatments capable of slowing the spread of infectious respiratory diseases. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 15, 2021 Category: Infectious Diseases Source Type: news

Ex-Celtics player suggests Kyrie Irving's ankle injury is karma after logo stomp
Former Boston Celtics player Glen Davis was less than sympathetic with Kyrie Irving on Sunday when the Brooklyn Nets star suffered an... (Source: Reuters: Health)
Source: Reuters: Health - June 14, 2021 Category: Consumer Health News Source Type: news

Compression socks enhance sensory feedback to improve standing balance reactions and reflex control of walking - Sun Y, Munro B, Zehr EP.
BACKGROUND: Compression garments are generally used for their potential benefits in exercise performance and post-exercise recovery. Previous studies show that compression sleeves worn at the elbow change neuromuscular control and improve performance durin... (Source: SafetyLit)
Source: SafetyLit - June 7, 2021 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Daily Insight: Gag reflex
The must-read stories and debate in health policy and leadership. (Source: HSJ)
Source: HSJ - May 21, 2021 Category: UK Health Source Type: news

Dr. Mary Nandili: A Voice and Vision for Nursing Leadership
By Dr. Mary Nandili, Director of nursing services ; The Editorial Team, IntraHealth International Dr. Mary Nandili is director of nursing services at Kenya's Ministry of Health and is responsible for the leadership and governance of nursing services in the country. Photo by Patrick Meinhardt for IntraHealth International.May 12, 2021Dr. Mary Nandili is the director of nursing services at the Kenya Ministry of Health, the highest-level nurse in the country. IntraHealth collaborates with Dr. Nandili and the Ministry of Health to deliver on its mandate to increase the graduating health workforce and improve the man...
Source: IntraHealth International - May 12, 2021 Category: International Medicine & Public Health Authors: cbales Tags: International Nurses Day Source Type: news

A Space in Time review – lyrical portrait of a family facing an incurable disorder
This poignant documentary about two young brothers with Duchenne muscular dystrophy celebrates the power of love and togethernessHere is a deeply personal documentary that raises awareness about a disability without neglecting the interiority of those living with the condition. Co-directed by Riccardo Servini and Nick Taussig, the film follows the Taussig family ’s experience of Duchenne muscular dystrophy, a genetic disorder that affects their young sons, Theo and Oscar.Duchenne is incurable and fatal. By the time Theo and Oscar are in their teens, they will be using wheelchairs full time; their 20s will come with v...
Source: Guardian Unlimited Science - May 10, 2021 Category: Science Authors: Phuong Le Tags: Film Documentary films Health Society Culture Genetics Science Children Parents and parenting Family Biology Life and style Source Type: news

Possible origin of neuroblastoma in the adrenal glands discovered
(Medical University of Vienna) Since the tumour cells of neuroblastoma resemble certain cells in the adrenal glands, a joint research group investigated the cellular origin of these cells and sympathetic neurons during the embryonic development of human adrenal glands. They discovered a previously unknown cell type that might potentially be the origin of the tumour cells. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 7, 2021 Category: International Medicine & Public Health Source Type: news

Mother and son share rare muscle disorder, treated decades apart by same doctor
Twenty-four years ago, Bobbi Heinold, 17, was diagnosed with facioscapulohumeral muscular dystrophy, a genetic muscle condition characterized by weakness, especially in the face, shoulder blades and upper arms. Doctors told her it could affect her quality of life. Bobbi and her mom drove from their Indiana home to Mayo Clinic in Rochester, Minnesota, to learn [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 6, 2021 Category: Databases & Libraries Source Type: news

The most savage memes about Bill and Melinda Gates' divorce
They opened the online flood-Gates: When the billionaire couple announced they were getting divorced Monday, the ever-sympathetic social... (Source: Reuters: Health)
Source: Reuters: Health - May 4, 2021 Category: Consumer Health News Source Type: news

Towards a treatment for myotonic dystrophy: First 3D model with patient cells
(Institute for Bioengineering of Catalonia (IBEC)) Researchers from the Institute for Bioengineering of Catalonia (IBEC) in collaboration with the INCLIVA Health Research Institute in Valencia, develop the first three-dimensional model for myotonic dystrophy, a rare disease that currently has no cure. The new model combines patient cells and bioengineering techniques and represents a major advance over the use of animals and cell cultures. This new model will help in the design of personalized and more effective treatments, and for drug testing in a much more efficient way. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 3, 2021 Category: Biology Source Type: news

A milestone in muscular dystrophy therapy
(Max Delbr ü ck Center for Molecular Medicine in the Helmholtz Association) A new gene-editing technique can be used to correct mutations in muscle stem cells, paving the way for the first potential cell therapy for genetic muscle disorders. The ECRC team led by Professor Simone Spuler have published their findings in the journal JCI Insight. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 30, 2021 Category: International Medicine & Public Health Source Type: news

CHMP recommends EU approval of Roche ’s ENSPRYNG (satralizumab) for adults and adolescents with neuromyelitis optica spectrum disorder (NMOSD)
Basel, 23 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ENSPRYNG® (satralizumab) as the first subcutaneous treatment option for adults and adolescents from 12 years of age living with anti-aquaporin-4 antibody (AQP4-IgG) seropositive neuromyelitis optica spe ctrum disorder (NMOSD), as a monotherapy or in combination with immunosuppressive therapy (IST). AQP4-IgG are present in around 70-80% of people with NMOSD, who tend to experience a more severe disease course.NMOS...
Source: Roche Media News - April 23, 2021 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s ENSPRYNG (satralizumab) for adults and adolescents with neuromyelitis optica spectrum disorder (NMOSD)
Basel, 23 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ENSPRYNG® (satralizumab) as the first subcutaneous treatment option for adults and adolescents from 12 years of age living with anti-aquaporin-4 antibody (AQP4-IgG) seropositive neuromyelitis optica spe ctrum disorder (NMOSD), as a monotherapy or in combination with immunosuppressive therapy (IST). AQP4-IgG are present in around 70-80% of people with NMOSD, who tend to experience a more severe disease course.NMOS...
Source: Roche Investor Update - April 23, 2021 Category: Pharmaceuticals Source Type: news

C-Path opens access to Duchenne Regulatory Science Consortium database
(Critical Path Institute (C-Path)) C-Path announced today that it will open access to the Duchenne Regulatory Science Consortium database to qualified researchers, through its Rare Disease Cures Accelerator, Data and Analytics Platform. The D-RSC database includes data from Duchenne muscular dystrophy clinical trials, natural history studies and clinical data collections. The contributors of these datasets have given permission for this data to be shared externally to accelerate therapy development for DMD. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 22, 2021 Category: International Medicine & Public Health Source Type: news

New data for Roche ’s OCREVUS (ocrelizumab) reinforce significant benefit on slowing disease progression in relapsing and primary progressive multiple sclerosis
Basel, 16 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new OCREVUS ® (ocrelizumab) analyses supporting its significant benefit on disease progression in early-stage relapsing-remitting multiple sclerosis (RRMS) and primary progressive MS (PPMS) as well as demonstrating high persistence and strong adherence to twice-yearly (six-monthly) dosing. These data are being presented virtually at the 73rd American Academy of Neurology (AAN) Annual Meeting from 17–22 April 2021. OCREVUS is the number one prescribed MS medication in the U.S. for patients starting a new treatment, and more than 200,000 peop...
Source: Roche Investor Update - April 16, 2021 Category: Pharmaceuticals Source Type: news

New data for Roche ’s OCREVUS (ocrelizumab) reinforce significant benefit on slowing disease progression in relapsing and primary progressive multiple sclerosis
Basel, 16 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new OCREVUS ® (ocrelizumab) analyses supporting its significant benefit on disease progression in early-stage relapsing-remitting multiple sclerosis (RRMS) and primary progressive MS (PPMS) as well as demonstrating high persistence and strong adherence to twice-yearly (six-monthly) dosing. These data are being presented virtually at the 73rd American Academy of Neurology (AAN) Annual Meeting from 17–22 April 2021. OCREVUS is the number one prescribed MS medication in the U.S. for patients starting a new treatment, and more than 200,000 peop...
Source: Roche Media News - April 16, 2021 Category: Pharmaceuticals Source Type: news

Novel muscular dystrophy gene connects to a key biological pathway
(University of Minnesota Medical School) New research from the University of Minnesota Medical School found mutations in a novel gene that may help identify patients with a specific form of muscular dystrophy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 15, 2021 Category: International Medicine & Public Health Source Type: news

New discovery could lead to therapies for patients with Duchenne muscular dystrophy
(University of California - Irvine) A new study, led by the University of California, Irvine (UCI), reveals how chronic inflammation promotes muscle fibrosis, which could inform the development of new therapies for patients suffering from Duchenne muscular dystrophy (DMD), a fatal muscle disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 14, 2021 Category: International Medicine & Public Health Source Type: news

Biotech company spun out of Ohio State University research raises $116M in latest round
A biotechnology company that spun out of Ohio State University research announced it raised more than $116 million in its latest financing round. Boston-based Entrada Therapeutics Inc., which was co-founded by an OSU professor, said the investment will support treating people with multiple neuromuscular diseases, including Duchenne muscular dystrophy. When it was founded in 2018, Entrada raised $59 million, which was the largest amount rai sed in an initial financing round for an OSU startup. The… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 5, 2021 Category: Biotechnology Authors: Hayleigh Colombo Source Type: news

A psychophysiological model of firearms training in police officers: a virtual reality experiment for biocybernetic adaptation - Mu ñoz JE, Quintero L, Stephens CL, Pope AT.
Crucial elements for police firearms training include mastering very specific psychophysiological responses associated with controlled breathing while shooting. Under high-stress situations, the shooter is affected by responses of the sympathetic nervous s... (Source: SafetyLit)
Source: SafetyLit - April 4, 2021 Category: International Medicine & Public Health Tags: Occupational Issues Source Type: news

Heightened Brain Activity With Stress Tied to Takotsubo Syndrome Heightened Brain Activity With Stress Tied to Takotsubo Syndrome
A higher ratio of amygdalar to regulatory brain activity may lead to heightened response to stressors, activation of the sympathetic and immune systems, and risk for so-called'broken heart syndrome. 'Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 29, 2021 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news

Chemical cocktail creates new avenues for muscle stem cell therapies
A UCLA-led research team has identified a chemical cocktail that enables the production of large numbers of muscle stem cells, which can self-renew and give rise to all types of skeletal muscle cells.The advance could lead to the development of stem cell-based therapies for muscle loss or damage due to injury, age or disease.The research was published in Nature Biomedical Engineering.Muscle stem cells are responsible for muscle growth, repair and regeneration following injury throughout a person ’s life. In fully grown adults, muscle stem cells are quiescent — they remain inactive until they are called to respo...
Source: UCLA Newsroom: Health Sciences - March 18, 2021 Category: Universities & Medical Training Source Type: news

When depression wears a smile, even psychiatrists like me can be deceived | Rebecca Lawrence
By the time mental ill health is visible, it ’s probably very bad. The best risk assessment is to listen rather than lookIn my everyday life, when I see someone who looks happy, I expect them to feel like that, too. I don ’t think about it particularly – it’s a reflex. I glance casually at a smiling face and am reassured that all is well. It takes a conscious effort to remind myself of a fact that psychiatrists know very well on an intellectual level but should perhaps recognise more: a cheerful demeanour can b e profoundly misleading.The concept of the “happy” depressive is familiar in ...
Source: Guardian Unlimited Science - March 18, 2021 Category: Science Authors: Rebecca Lawrence Tags: Mental health UK news Depression Psychiatry Psychology Society Science Source Type: news

New two-year data show Roche ’s Evrysdi (risdiplam) continues to demonstrate improvement or maintenance of motor function in people aged 2-25 with Type 2 or Type 3 Spinal Muscular Atrophy (SMA)
Basel, 16 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new exploratory 2-year longer-term data from Part 2 of SUNFISH, a global placebo-controlled study evaluating Evrysdi ™ (risdiplam) in people aged 2-25 years with Type 2 or non-ambulant Type 3 spinal muscular atrophy (SMA). The study suggests that gains in motor function observed with Evrysdi treatment at month 12 continued to improve or were maintained at month 24 across primary and secondary endpoint measures. Based on the natural history of the disease, people with Types 2 and 3 SMA who remain untreated decline in motor function over time. Th...
Source: Roche Investor Update - March 16, 2021 Category: Pharmaceuticals Source Type: news

New two-year data show Roche ’s Evrysdi (risdiplam) continues to demonstrate improvement or maintenance of motor function in people aged 2-25 with Type 2 or Type 3 Spinal Muscular Atrophy (SMA)
Basel, 16 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new exploratory 2-year longer-term data from Part 2 of SUNFISH, a global placebo-controlled study evaluating Evrysdi ™ (risdiplam) in people aged 2-25 years with Type 2 or non-ambulant Type 3 spinal muscular atrophy (SMA). The study suggests that gains in motor function observed with Evrysdi treatment at month 12 continued to improve or were maintained at month 24 across primary and secondary endpoint measures. Based on the natural history of the disease, people with Types 2 and 3 SMA who remain untreated decline in motor function over time. Th...
Source: Roche Media News - March 16, 2021 Category: Pharmaceuticals Source Type: news

A rare trigger for photosensitive seizure: fireworks - G ürbüz G, Gürbüz B.
Reflex epilepsy is a type of epilepsy involving seizures that occur with sensory stimulus. It occurs when the cortical and subcortical brain areas over-react to a physiological stimulus. Stimulus can be simple like flickering lights, hot water or complex l... (Source: SafetyLit)
Source: SafetyLit - March 13, 2021 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

An atypical presentation of sympathetic ophthalmia in an intact globe following mechanical fall: a case report and literature review - Chean CS, Lim CS, Kumar P, Kapoor B.
PURPOSE: To describe an atypical case of sympathetic ophthalmia presenting after blunt trauma causing disinsertion of the iris in an intact globe. METHODS: Case report. RESULTS: A 71-year-old lady presented to the Emergency Department follo... (Source: SafetyLit)
Source: SafetyLit - March 12, 2021 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Physician Support Line: One Psychiatrist Making a Difference Physician Support Line: One Psychiatrist Making a Difference
A Pennsylvania psychiatrist has started a peer-to-peer physician support hotline with psychiatrist volunteers providing a sympathetic ear.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 5, 2021 Category: Consumer Health News Tags: Psychiatry News Source Type: news

A new blindness gene uncovered in a canine study
(University of Helsinki) A study recently completed at the University of Helsinki has uncovered a mutation in the IFT122 gene in blind dogs. The gene defect now discovered results in the progressive destruction of photoreceptor cells and retinal dystrophy. IFT122 is a new candidate also for retinal dystrophy in humans. A gene test in support of breeding and diagnostics has been developed based on the finding. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 2, 2021 Category: International Medicine & Public Health Source Type: news

Translating passion into execution: Cure Rare Disease's founder on the business of biotech
When a career path chooses you in the form of a pressing personal cause, passion and commitment must soon be followed by execution. And that means schooling up — quickly. I had heard the call of entrepreneurship early. I had a new Harvard Business School degree in hand at the same time my brother’s health was declining steeply due to Duchenne muscular dystrophy. His fatal degenerative neuromuscular condition wouldn't wait, and the lack of viable option s in the pipeline for his gene mutation required entrepreneurial thinking. The science would come. I was in Boston, after all, immersed in bioscience. And it has...
Source: bizjournals.com Health Care:Biotechnology headlines - February 26, 2021 Category: Biotechnology Authors: Rich Horgan Source Type: news

FDA OKs First'Targeted Treatment' for Rare DMD Mutation FDA OKs First'Targeted Treatment' for Rare DMD Mutation
The FDA has approved casimersen (Amondys 45) injection for treating patients with both Duchenne muscular dystrophy (DMD) and a rare mutation of the DMD gene.FDA Approvals (Source: Medscape Pediatrics Headlines)
Source: Medscape Pediatrics Headlines - February 26, 2021 Category: Pediatrics Tags: Neurology & Neurosurgery News Alert Source Type: news

FDA Approves Amondys 45 (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45
CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Amondys 45... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 25, 2021 Category: Drugs & Pharmacology Source Type: news

For UCLA-based startup, new muscular dystrophy treatment is a personal mission
Courtney Young helped develop the gene therapy at the heart of a biotech startup,MyoGene Bio, when she was a doctoral student at UCLA from 2013 to 2018. But the kernel of the company ’s endeavor is older still — and definitively personal.In 2008, when Young was in high school, she found out that her cousin, then just a toddler, had been diagnosed with Duchenne muscular dystrophy. She made it her mission to cultivate the skills needed to provide better options for him and others who were suffering with the deadly muscle-wasting disease.“I directed my career toward working on Duchenne,” said Young, My...
Source: UCLA Newsroom: Health Sciences - February 23, 2021 Category: Universities & Medical Training Source Type: news

After the Nobel, what next for Crispr  gene-editing therapies?
Hailed as the ‘molecular scissors’ that will allow us to rewrite our genes, the DNA tool is being trialled in treatments for everything from sickle-cell anaemia to cancerWhen last year ’s Nobel prize for chemistry was awarded tobiochemist Jennifer Doudna and microbiologist Emmanuelle Charpentier for their work in developing the technique of gene editing known as Crispr-Cas9 (pronounced “crisper”), headlines hailed their discovery as “molecular scissors” that would allow us to “rewrite the book of life” – with all the complicated ethical questions that ability rais...
Source: Guardian Unlimited Science - February 21, 2021 Category: Science Authors: Philip Ball Tags: Gene editing Medical research Genetics Biology Science Cancer Huntington's disease Sickle cell disease Source Type: news

Invitation to Roche ’s virtual event on 24-month data of Evrysdi in patients with type 2 or type 3 spinal muscular atrophy presented at the 2021 MDA virtual conference
We are pleased to invite investors and analysts to participate in our virtual event on Friday, 19 March, 2021, highlighting Roche data presented during the 2021 Muscular Dystrophy Association - MDA -Virtual Clinical and Scientific Conference, from 15th to 18th February. (Source: Roche Investor Update)
Source: Roche Investor Update - February 19, 2021 Category: Pharmaceuticals Source Type: news

Sir Peter Harper obituary
Researcher into the genetics of neurological disorders whose work has provided hope for a cure for muscular dystrophyPeter Harper, who has died aged 81, was a world expert on the genetics of inherited neurological disorders, particularlyHuntington ’s disease andmuscular dystrophy. He also advocated the idea of genetic counselling – helping people to understand the implications of inherited disorders that might affect them and their families.Finding a genetic link between the two wasting conditions has led to highly accurate diagnostic and predictive tests for at-risk individuals and their families. Peter played...
Source: Guardian Unlimited Science - February 15, 2021 Category: Science Authors: Peter McGuffin Tags: Genetics Medicine Science Education Biology Huntington's disease Source Type: news